What is Evoke+?

Evoke+ is a clinical study involving approximately 1840 people from 40 countries worldwide.

The **Evoke+** study is conducted to investigate if semaglutide can prevent progressive loss of cognition and function in patients with early Alzheimer's disease. Usage of semaglutide in oral formulation is already approved for the treatment of type 2 diabetes mellitus (T2DM) in several countries. Currently there are no treatments available for the treatment of Mild Cognitive Impairment (MCI) and only symptomatic treatments are available for dementia due to Alzheimer's disease, which therefore signifies to the importance of finding a treatment that can target and even prevent the early stages of dementia. The **Evoke+** study will examine the effects of semaglutide on the change in cognition and function in people with early Alzheimer's disease.

What are the benefits of taking part in evoke?

There are several potential benefits of taking part in **Evoke+** such as:

- Taking a more active role in your own healthcare
- Getting regular expert medical care at health care facilities
- Having additional talks with the study staff to discuss healthy lifestyle choices
- Helping others by contributing to medical research

What are the potential downsides?

There may be some potential downsides to taking the study medicine:

- You may experience side effects
- Your study medicine may prove to be ineffective against improvement of the memory
- The study may require more of your and your study partners time and attention, than normal treatment and may include extra clinic visits or more complex treatment requirements

You should tell your study doctor or the study staff about any side effects or health problems you have, while taking part in the study, even if you do not think they are caused by the study medicine.

Before participating in a clinical study such as **Evoke+**, the study doctor or study staff will provide both verbal and written information about the study, including comprehensive

information about the potential risks and benefits, to allow you to make an informed choice about your participation.

What will be required if I take part?

Initially, you will go through a screening process to ensure that you meet the criteria for being included in the **Evoke**+ study. If you do, your study doctor will explain exactly what is expected of a study participant so you can make an informed decision. Participation in the **Evoke**+ study will include:

- A daily dose of the study medicine, prescribed by the study doctor
- Attending regular study visits for study-related health checks and examinations
- Undergoing an MRI or CT scan
- Undergoing a PET scan or a lumbar puncture test
- Regular contact with the study nurse or the study doctor throughout the study

Will I know if I have placebo or the real medicine?

Evoke+ is a "placebo-controlled" study, which, means half of the people in the study will be given a "dummy" medicine called a placebo.

- You will be randomly assigned to either the study medicine (semaglutide) or the placebo for the full length of the study.
- You will not know which medicine you have, and neither will your study doctor or the study team.

At the end of the study, you will be told which medicine you were given. You will also have an opportunity to see the results of the study.

How do my personal study results contribute to the final study results?

The information collected from you during the study is made anonymous and entered a database together with information from everyone else in the study. It is then analysed by doctors and scientists.

For the results to be meaningful, it is very important that everybody in the study continues until the end.

Do I need to attend every study visit?

The **Evoke**+ study will last for up to 3 years in order to get a clear understanding of the effects of the study medicine over time. Attending regular study visits will help us to understand the effect of the medicine, as well as giving you the opportunity to discuss any health-related questions or concerns with your study doctor.

Should I still go to my clinic visits if I stop taking the study medicine?

Even if you or your study doctor make the decision to stop taking the study medicine ahead of schedule, it is still very important for you to attend as many visits as possible until the end of the study. Valuable information can still be collected, and the study doctors can monitor your progress and health. Every patient's information is important for the overall success of the study.

Will being in the Evoke+ study affect my other medicines?

No, you will continue to take any other prescribed medicines throughout the study as required.

What should I do if I become pregnant during the study?

You should not take part in this study if you are pregnant, breastfeeding, or planning to get pregnant. If you become pregnant during the study, you should stop taking your study medicine immediately and tell the study staff.

Is my personal and medical information confidential?

Your information is protected and treated with confidentiality and will remain anonymous. In some countries, your personal information may be shared with a search agency. This will only happen if the study staff loses contact with you.

Will I get paid?

You may receive some compensation for your time and inconvenience of taking part in the study, the patient information sheet provides details of this. You may be reimbursed for travel expenses- please speak to the study staff about reimbursement.

Will I be helping others?

Choosing to take part in a clinical study is an important decision. By attending your study visits, you will help us understand how safe the study medicine is, and how well it works. The results from this study will inform treatment for other people with early Alzheimer's disease.

You will be able to discuss the visits with your study doctor and organise times that work best for your schedule. You may also be able to phone the site for some visits, rather than attending in person.